These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
463 related articles for article (PubMed ID: 28739436)
41. Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study. Schein YL; Madebo T; Andersen HE; Arnesen TM; Dyrhol-Riise AM; Tveiten H; White RA; Winje BA BMC Infect Dis; 2018 Nov; 18(1):587. PubMed ID: 30453946 [TBL] [Abstract][Full Text] [Related]
42. Is Universal Screening Necessary? Incidence of Tuberculosis among Tibetan Refugees Arriving in Calgary, Alberta. Lim R; Jarand J; Field SK; Fisher D Can Respir J; 2016; 2016():8249843. PubMed ID: 28127230 [No Abstract] [Full Text] [Related]
43. Latent Tuberculosis in Pregnancy: A Systematic Review. Malhamé I; Cormier M; Sugarman J; Schwartzman K PLoS One; 2016; 11(5):e0154825. PubMed ID: 27149116 [TBL] [Abstract][Full Text] [Related]
44. Completion of treatment for latent tuberculosis infection with monthly drug dispensation directly through the tuberculosis clinic. Dobler CC; Marks GB PLoS One; 2012; 7(11):e48900. PubMed ID: 23139824 [TBL] [Abstract][Full Text] [Related]
45. A Step toward Tuberculosis Elimination in a Low-Incidence Country: Successful Diagnosis and Treatment of Latent Tuberculosis Infection in a Refugee Clinic. Rennert-May E; Hansen E; Zadeh T; Krinke V; Houston S; Cooper R Can Respir J; 2016; 2016():7980869. PubMed ID: 27445565 [TBL] [Abstract][Full Text] [Related]
46. Active case finding and prevention of tuberculosis among a cohort of contacts exposed to infectious tuberculosis cases in New York City. Anger HA; Proops D; Harris TG; Li J; Kreiswirth BN; Shashkina E; Ahuja SD Clin Infect Dis; 2012 May; 54(9):1287-95. PubMed ID: 22412056 [TBL] [Abstract][Full Text] [Related]
47. National position statement for the management of latent tuberculosis infection. Stock D; Commun Dis Intell Q Rep; 2017 Sep; 41(3):E204-E208. PubMed ID: 29720068 [TBL] [Abstract][Full Text] [Related]
49. Immigrant screening for latent tuberculosis in Norway: a cost-effectiveness analysis. Haukaas FS; Arnesen TM; Winje BA; Aas E Eur J Health Econ; 2017 May; 18(4):405-415. PubMed ID: 26970772 [TBL] [Abstract][Full Text] [Related]
50. Seven-year retrospective study understanding the latent TB infection treatment cascade of care among adults in a low incidence country. Sullivan K; Pease C; Zwerling A; Mallick R; Van Dyk D; Mulpuru S; Allen C; Alsdurf H; Alvarez GG BMC Public Health; 2021 May; 21(1):964. PubMed ID: 34020616 [TBL] [Abstract][Full Text] [Related]
51. Prevalence of LTBI in patients with autoimmune diseases and accuracy of IGRA in predicting TB relapse. Chandrashekara S; Panchagnula R; Chennupati Y Rheumatology (Oxford); 2023 Dec; 62(12):3952-3956. PubMed ID: 37348542 [TBL] [Abstract][Full Text] [Related]
52. Long-term performance of the IGRA to predict and prevent active tuberculosis development in HIV-infected patients. Lee S; Lee JE; Kang JS; Lee SO; Lee SH Int J Tuberc Lung Dis; 2019 Apr; 23(4):422-427. PubMed ID: 31064620 [TBL] [Abstract][Full Text] [Related]
53. Management of Latent Tuberculosis Infection in Children from Developing Countries. Jain A; Lodha R Indian J Pediatr; 2019 Aug; 86(8):740-745. PubMed ID: 30741387 [TBL] [Abstract][Full Text] [Related]
54. Primary Care Screening and Treatment for Latent Tuberculosis Infection in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force. Kahwati LC; Feltner C; Halpern M; Woodell CL; Boland E; Amick HR; Weber RP; Jonas DE JAMA; 2016 Sep; 316(9):970-83. PubMed ID: 27599332 [TBL] [Abstract][Full Text] [Related]
55. Using Spatial Disease Patterns and Patient-Level Characteristics to Describe Prevalence Elastic Behavior in Treatment for Latent Tuberculosis Infection (LTBI). Fluegge KR Public Health Nurs; 2015; 32(5):517-31. PubMed ID: 25655175 [TBL] [Abstract][Full Text] [Related]
57. Incidence and risk factors of active tuberculosis among older individuals with latent tuberculosis infection: a cohort study in two high-epidemic sites in eastern China. Zhu P; Hao X; Wang W; Wang W; Xu B; Zhan B; Fang C; Zhang Y; Gao Y; Chen B Front Cell Infect Microbiol; 2024; 14():1332211. PubMed ID: 38741890 [TBL] [Abstract][Full Text] [Related]
58. Role of interferon-gamma release assay for screening and monitoring of latent tuberculosis infection in kidney transplant recipients. Bruminhent J; Treekajonsak T; Kantachuvesiri S; Setthaudom C; Sukkasem W; Kawamatawong T BMC Infect Dis; 2024 Oct; 24(1):1110. PubMed ID: 39375585 [TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of short-term treatment with isoniazid and rifampicin for latent tuberculosis infection in lung transplant candidates. Guirao-Arrabal E; Santos F; Redel J; Vaquero JM; Torre-Cisneros J Clin Transplant; 2017 Mar; 31(3):. PubMed ID: 28008662 [TBL] [Abstract][Full Text] [Related]
60. Effect of isoniazid preventive therapy on tuberculosis incidence and associated risk factors among HIV infected adults in Tanzania: a retrospective cohort study. Sabasaba A; Mwambi H; Somi G; Ramadhani A; Mahande MJ BMC Infect Dis; 2019 Jan; 19(1):62. PubMed ID: 30654753 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]